Product logins

Find logins to all Clarivate products below.


Acute Heart Failure – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF and the diagnosed prevalence of CHF for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s HF forecast answers the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with severe disease?
  • Of all AHF hospitalization events, how many in each of the major mature pharmaceutical markets are drug-treated?
  • Of all people diagnosed with CHF, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of HF over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HF subpopulations:

  • Diagnosed AHF events by ejection fraction.
  • Diagnosed AHF events by treatment status.
  • Diagnosed AHF events by subpopulation.
  • Diagnosed CHF prevalent cases by severity.
  • Diagnosed CHF prevalent cases by treatment scheme.
  • Diagnosed CHF prevalent cases by ejection fraction.
  • Diagnosed CHF prevalent cases by comorbidity.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
Report
Heart Failure – Landscape & Forecast – Disease Landscape & Forecast (G7)
Heart failure (HF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. Acute heart failure (AHF) and…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…